Statistics for ETS REVISIÓN RÁPIDA N° 42-2021. Adalimumab, golimumab, infliximab, tocilizumab, etanercept y rituximab: tratamiento de pacientes con artritis reumatoide refractaria al tratamiento convencional
Total visits
| views | |
|---|---|
| ETS REVISIÓN RÁPIDA N° 42-2021. Adalimumab, golimumab, infliximab, tocilizumab, etanercept y rituximab: tratamiento de pacientes con artritis reumatoide refractaria al tratamiento convencional | 61 |
Total visits per month
| views | |
|---|---|
| October 2024 | 14 |
| November 2024 | 4 |
| December 2024 | 8 |
| January 2025 | 13 |
| February 2025 | 6 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| REVISION_RAPIDA_042_2021 | 32 |